Symbols / COCP
COCP Chart
About
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 13.71M |
| Enterprise Value | 7.57M | Income | -9.67M | Sales | — |
| Book/sh | 0.59 | Cash/sh | 0.56 | Dividend Yield | — |
| Payout | 0.00% | Employees | 11 | IPO | — |
| P/E | — | Forward P/E | -1.20 | PEG | — |
| P/S | — | P/B | 1.69 | P/C | — |
| EV/EBITDA | -0.78 | EV/Sales | — | Quick Ratio | 5.42 |
| Current Ratio | 5.78 | Debt/Eq | 20.64 | LT Debt/Eq | — |
| EPS (ttm) | -0.93 | EPS next Y | -0.83 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 08:00 | ROA | -45.77% |
| ROE | -94.94% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 13.78M |
| Shs Float | 9.14M | Short Float | 1.78% | Short Ratio | 2.19 |
| Short Interest | — | 52W High | 2.67 | 52W Low | 0.86 |
| Beta | 1.21 | Avg Volume | 73.68K | Volume | 40.95K |
| Target Price | $6.67 | Recom | Strong_buy | Prev Close | $1.01 |
| Price | $0.99 | Change | -1.49% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.67
Mean price target
2. Current target
$1.00
Latest analyst target
3. DCF / Fair value
$-7.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.00
Low
$6.00
High
$8.00
Mean
$6.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-06-20 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-01-03 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2023-12-04 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-10-04 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-06-02 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-05-24 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2023-01-24 | main | HC Wainwright & Co. | — → Buy | $35 |
| 2022-11-07 | main | HC Wainwright & Co. | — → Buy | $42 |
- Phillip Frost buys Cocrystal Pharma (COCP) shares worth $3975 - Investing.com Fri, 28 Nov 2025 08
- Human trial of first oral drug to fight norovirus cleared at Emory - Stock Titan hu, 18 Dec 2025 08
- How COCP stock trades before earnings - 2025 AllTime Highs & Daily Stock Trend Reports - mfd.ru Sun, 15 Feb 2026 19
- Insider Makes Bold Move on Cocrystal Pharma Shares - TipRanks Fri, 02 Jan 2026 08
- Phillip Frost buys Cocrystal Pharma (COCP) shares worth $63k - Investing.com Mon, 29 Dec 2025 08
- Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation - Yahoo Finance Fri, 18 Oct 2024 07
- Tuesday’s Insider Activity: Major Buys at CBC, COCP; Sells at ARES, RKLB - Investing.com South Africa Wed, 26 Nov 2025 08
- Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus - GlobeNewswire hu, 18 Dec 2025 08
- COCP Stock Price and Chart — NASDAQ:COCP - TradingView Wed, 14 Mar 2018 04
- Is Cocrystal Pharma, Inc. (COCP) A Good Stock To Buy? - Insider Monkey Sun, 29 Nov 2020 08
- Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza - Stock Titan Wed, 01 May 2024 07
- NASDAQ Penny Stocks to Keep an Eye On: BLRX COCP LEDS REED - Insider Financial hu, 06 May 2021 07
- Cocrystal Highlights CDI-988 Norovirus Data at ICAR 2026 - TipRanks hu, 19 Feb 2026 14
- Can Whitehawk Therapeutics Inc. (3350) stock sustain double digit ROE - July 2025 Chart Watch & Low Risk Entry Point Guides - mfd.ru ue, 17 Feb 2026 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 50000 | 47280 | — | Purchase at price 0.95 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-06 00:00:00 | I |
| 1 | 50000 | 47275 | — | Purchase at price 0.95 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-31 00:00:00 | I |
| 2 | 20000 | 19310 | — | Purchase at price 0.97 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-30 00:00:00 | I |
| 3 | 65000 | 63202 | — | Purchase at price 0.97 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-26 00:00:00 | I |
| 4 | 4000 | 3975 | — | Purchase at price 0.99 - 1.00 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-26 00:00:00 | I |
| 5 | 20000 | 18812 | — | Purchase at price 0.94 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-25 00:00:00 | I |
| 6 | 3598 | 4138 | — | Stock Award(Grant) at price 1.15 per share. | MARTIN JAMES J. CPA | Chief Executive Officer | — | 2025-10-28 00:00:00 | D |
| 7 | 359713 | 413670 | — | Stock Award(Grant) at price 1.15 per share. | FROST PHILLIP MD ET AL | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-28 00:00:00 | I |
| 8 | 359713 | 413670 | — | Stock Award(Grant) at price 1.15 per share. | HASSAN FRED | Director | — | 2025-10-28 00:00:00 | D |
| 9 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | PFENNIGER RICHARD C JR | Director | — | 2025-10-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -17.27M | -23.69M | 2.95M | -13.84M |
| TotalUnusualItems | -163.00K | 2.54M | -20.70M | 40.00K |
| TotalUnusualItemsExcludingGoodwill | -163.00K | 2.54M | -20.70M | 40.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.50M | -17.98M | -38.84M | -14.19M |
| ReconciledDepreciation | 446.00K | -1.39M | 388.00K | 382.00K |
| EBITDA | -17.43M | -21.16M | -17.75M | -13.80M |
| EBIT | -17.88M | -21.16M | -18.14M | -14.18M |
| NetInterestIncome | 537.00K | 640.00K | -2.00K | -4.00K |
| InterestExpense | 2.00K | 4.00K | ||
| NormalizedIncome | -17.34M | -20.52M | -18.14M | -14.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.50M | -17.98M | -38.84M | -14.19M |
| TotalExpenses | 17.88M | 21.16M | 18.14M | 14.22M |
| TotalOperatingIncomeAsReported | -17.88M | -18.56M | -38.83M | -14.22M |
| DilutedAverageShares | 10.17M | 9.65M | 8.14M | 7.36M |
| BasicAverageShares | 10.17M | 9.65M | 8.14M | 7.36M |
| DilutedEPS | -1.72 | -1.87 | -4.77 | -0.16 |
| BasicEPS | -1.72 | -1.87 | -4.77 | -0.16 |
| DilutedNIAvailtoComStockholders | -17.50M | -17.98M | -38.84M | -14.19M |
| NetIncomeCommonStockholders | -17.50M | -17.98M | -38.84M | -14.19M |
| NetIncome | -17.50M | -17.98M | -38.84M | -14.19M |
| NetIncomeIncludingNoncontrollingInterests | -17.50M | -17.98M | -38.84M | -14.19M |
| NetIncomeContinuousOperations | -17.50M | -17.98M | -38.84M | -14.19M |
| PretaxIncome | -17.50M | -17.98M | -38.84M | -14.19M |
| OtherIncomeExpense | -163.00K | 2.54M | -20.70M | 40.00K |
| SpecialIncomeCharges | 0.00 | 2.60M | -20.69M | 0.00 |
| OtherSpecialCharges | -2.60M | 1.60M | ||
| ImpairmentOfCapitalAssets | 0.00 | 19.09M | 0.00 | |
| GainOnSaleOfSecurity | -163.00K | -65.00K | -6.00K | 40.00K |
| NetNonOperatingInterestIncomeExpense | 537.00K | 640.00K | -2.00K | -4.00K |
| TotalOtherFinanceCost | -537.00K | -640.00K | 2.00K | |
| InterestExpenseNonOperating | 2.00K | 4.00K | ||
| OperatingIncome | -17.88M | -21.16M | -18.14M | -14.22M |
| OperatingExpense | 17.88M | 21.16M | 18.14M | 14.22M |
| ResearchAndDevelopment | 12.54M | 15.17M | 12.39M | 8.79M |
| SellingGeneralAndAdministration | 5.34M | 5.99M | 5.75M | 5.43M |
| GeneralAndAdministrativeExpense | 5.34M | 5.99M | 5.75M | 5.43M |
| OtherGandA | 5.34M | 5.99M | 5.75M | 5.43M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 10.17M | 10.17M | 8.14M | 8.12M |
| ShareIssued | 10.17M | 10.17M | 8.14M | 8.12M |
| TotalDebt | 1.81M | 1.85M | 297.00K | 534.00K |
| TangibleBookValue | 9.52M | 26.38M | 39.57M | 58.46M |
| InvestedCapital | 9.52M | 26.38M | 39.57M | 77.55M |
| WorkingCapital | 9.15M | 25.83M | 38.96M | 57.78M |
| NetTangibleAssets | 9.52M | 26.38M | 39.57M | 58.46M |
| CapitalLeaseObligations | 1.81M | 1.85M | 297.00K | 534.00K |
| CommonStockEquity | 9.52M | 26.38M | 39.57M | 77.55M |
| TotalCapitalization | 9.52M | 26.38M | 39.57M | 77.55M |
| TotalEquityGrossMinorityInterest | 9.52M | 26.38M | 39.57M | 77.55M |
| StockholdersEquity | 9.52M | 26.38M | 39.57M | 77.55M |
| RetainedEarnings | -333.42M | -315.91M | -297.93M | -259.09M |
| AdditionalPaidInCapital | 342.93M | 342.29M | 337.49M | 336.63M |
| CapitalStock | 10.00K | 10.00K | 8.00K | 8.00K |
| CommonStock | 10.00K | 10.00K | 8.00K | 8.00K |
| TotalLiabilitiesNetMinorityInterest | 3.93M | 4.88M | 1.27M | 1.84M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.50M | 1.61M | 57.00K | 298.00K |
| LongTermDebtAndCapitalLeaseObligation | 1.50M | 1.61M | 57.00K | 298.00K |
| LongTermCapitalLeaseObligation | 1.50M | 1.61M | 57.00K | 298.00K |
| CurrentLiabilities | 2.43M | 3.26M | 1.22M | 1.54M |
| OtherCurrentLiabilities | 12.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 301.00K | 240.00K | 240.00K | 236.00K |
| CurrentCapitalLeaseObligation | 301.00K | 240.00K | 240.00K | 236.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 117.00K | 109.00K | 130.00K | 104.00K |
| PayablesAndAccruedExpenses | 2.01M | 2.91M | 846.00K | 1.19M |
| CurrentAccruedExpenses | 468.00K | 1.69M | 232.00K | 615.00K |
| Payables | 1.54M | 1.22M | 614.00K | 578.00K |
| AccountsPayable | 1.54M | 1.22M | 614.00K | 578.00K |
| TotalAssets | 13.46M | 31.26M | 40.84M | 79.39M |
| TotalNonCurrentAssets | 1.88M | 2.17M | 662.00K | 20.07M |
| NonCurrentPrepaidAssets | 29.00K | 46.00K | 46.00K | 46.00K |
| GoodwillAndOtherIntangibleAssets | 0.00 | 19.09M | ||
| Goodwill | 0.00 | 19.09M | ||
| NetPPE | 1.85M | 2.12M | 616.00K | 931.00K |
| AccumulatedDepreciation | -1.93M | -1.80M | -1.61M | -1.43M |
| GrossPPE | 3.78M | 3.92M | 2.23M | 2.36M |
| OtherProperties | 3.62M | 3.77M | 2.10M | 2.23M |
| MachineryFurnitureEquipment | 155.00K | 155.00K | 131.00K | 131.00K |
| CurrentAssets | 11.58M | 29.09M | 40.18M | 59.32M |
| OtherCurrentAssets | 430.00K | 1.77M | 2.24M | 568.00K |
| RestrictedCash | 75.00K | 75.00K | 75.00K | 50.00K |
| PrepaidAssets | 568.00K | |||
| Receivables | 1.22M | 890.00K | 716.00K | 0.00 |
| TaxesReceivable | 1.22M | 890.00K | 716.00K | 0.00 |
| AccountsReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 9.86M | 26.35M | 37.14M | 58.70M |
| CashAndCashEquivalents | 9.86M | 26.35M | 37.14M | 58.70M |
| CashFinancial | 9.86M | 26.35M | 37.14M | 58.70M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.49M | -14.78M | -21.51M | -12.77M |
| RepaymentOfDebt | 0.00 | -7.00K | -27.00K | -39.00K |
| IssuanceOfCapitalStock | 0.00 | 4.00M | 0.00 | 38.51M |
| CapitalExpenditure | -8.00K | -118.00K | -74.00K | -52.00K |
| EndCashPosition | 9.94M | 26.43M | 37.22M | 58.76M |
| BeginningCashPosition | 26.43M | 37.22M | 58.76M | 33.06M |
| ChangesInCash | -16.49M | -10.79M | -21.54M | 25.70M |
| FinancingCashFlow | 0.00 | 3.99M | -27.00K | 38.47M |
| CashFlowFromContinuingFinancingActivities | 0.00 | 3.99M | -27.00K | 38.47M |
| NetCommonStockIssuance | 0.00 | 4.00M | 0.00 | 38.51M |
| CommonStockIssuance | 0.00 | 4.00M | 0.00 | 38.51M |
| NetIssuancePaymentsOfDebt | 0.00 | -7.00K | -27.00K | -39.00K |
| NetLongTermDebtIssuance | 0.00 | -7.00K | -27.00K | -39.00K |
| LongTermDebtPayments | 0.00 | -7.00K | -27.00K | -39.00K |
| InvestingCashFlow | -8.00K | -118.00K | -74.00K | -52.00K |
| CashFlowFromContinuingInvestingActivities | -8.00K | -118.00K | -74.00K | -52.00K |
| NetPPEPurchaseAndSale | -8.00K | -118.00K | -74.00K | -52.00K |
| PurchaseOfPPE | -8.00K | -118.00K | -74.00K | -52.00K |
| OperatingCashFlow | -16.48M | -14.67M | -21.43M | -12.72M |
| CashFlowFromContinuingOperatingActivities | -16.48M | -14.67M | -21.43M | -13.15M |
| ChangeInWorkingCapital | 140.00K | 2.34M | -2.71M | 170.00K |
| ChangeInOtherCurrentAssets | 192.00K | |||
| ChangeInPayablesAndAccruedExpense | -895.00K | 2.05M | -321.00K | -217.00K |
| ChangeInPrepaidAssets | 1.36M | 470.00K | -1.68M | -169.00K |
| ChangeInReceivables | -325.00K | -174.00K | -716.00K | 556.00K |
| ChangesInAccountReceivables | 0.00 | 556.00K | ||
| OtherNonCashItems | -210.00K | 1.56M | -209.00K | 239.00K |
| StockBasedCompensation | 643.00K | 801.00K | 855.00K | 724.00K |
| AssetImpairmentCharge | 0.00 | 19.09M | 0.00 | |
| DepreciationAmortizationDepletion | 446.00K | -1.39M | 388.00K | 382.00K |
| DepreciationAndAmortization | 446.00K | -1.39M | 388.00K | 382.00K |
| Depreciation | 446.00K | -1.39M | 388.00K | 382.00K |
| OperatingGainsLosses | -12.00K | -49.00K | ||
| GainLossOnInvestmentSecurities | -12.00K | -49.00K | ||
| NetIncomeFromContinuingOperations | -17.50M | -17.98M | -38.84M | -14.19M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for COCP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|